Entering text into the input field will update the search result below

REGENXBIO patent case may weigh on Sarepta, according to Morgan Stanley

Feb. 09, 2021 2:34 PM ETREGENXBIO Inc. (RGNX) Stock, SRPT StockSRPT, RGNXBy: Jonathan Block, SA News Editor4 Comments
  • Morgan Stanley analyst Matthew Harrison writes that a patent case filed by REGENXBIO Inc. (NASDAQ:RGNX) against Sarepta Therapeutics (NASDAQ:SRPT) regarding SRP-9001 and SRP-9003 could have implications for the company.
  • In late December, a federal judge denied a motion from Sarepta

Recommended For You

Related Stocks

SymbolLast Price% Chg
SRPT
--
RGNX
--